8th

Urologic Oncology:Advances in Clinical Practice

November 8–9, 2013

MD Anderson Dan L. Duncan BuildingConference Center, Floor 8 1155 PresslerHouston, Texas

FocusThe 8th Urologic Oncology Conference will focus on the diagnosis, treatment, clinical advances, and controversies in localized and advanced bladder, prostate, kidney, penile and testis cancers.

Educational ObjectivesAfter attending the conference, participants should be able to• Implementandillustrateclinicaladvancesinthediagnosisandevaluation

ofbladder,prostate,kidney,penileandtestiscancers(Knowledge, Competence, Performance, Patient Outcomes);

• Implementandillustrateclinicaladvancesinthetreatmentapproachtolocalizedandlocallyadvancedbladder,prostate,kidney,penileandtestiscancers(Knowledge, Competence, Performance, Patient Outcomes);

• Implementandillustrateclinicaladvancesinthetreatmentapproachtometastaticbladder,prostate,kidney,penileandtestiscancers(Knowledge, Competence, Performance, Patient Outcomes);

• Identifyandaccesscontemporarycontroversiesinthemanagementofbladder,prostate,kidney,penileandtestiscancers(Knowledge, Competence).

Educational MethodsLectures – Case Presentations – Panel Discussions – Audience Response System – Question and Discussion Sessions

8th Urologic Oncology: Advances in Clinical PracticeNovember 8-9, 2013

Target AudienceThis conference should be of value to urologists, medical oncologists, nurses, nurse practitioners, and physician assistants.

EvaluationAcourseevaluationformwillprovideparticipantswiththeopportunitytocommentonthevalueoftheprogramcontenttotheirpracticedecisions,performanceimprovementactivities,orpossibleimpactonpatienthealthstatus.Participantswillalsohavetheopportunitytocommentonanyperceivedcommercialbiasinthepresentationsaswellastoidentifyfutureeducationaltopics.

Accreditation/Credit DesignationPhysiciansTheUniversityofTexasMDAndersonCancerCenterisaccreditedbytheAccreditationCouncilforContinuingMedicalEducationtoprovidecontinuingmedicaleducationforphysicians.

TheUniversityofTexasMDAndersonCancerCenterdesignatesthisliveactivityforamaximumof15.75AMA PRA Category 1 Credits TM.Physiciansshouldclaimonlythecreditcommensuratewiththeextentoftheirparticipationintheactivity.

CME Certificates and Attendance Verification CertificatesCertificatesawardingAMA PRA Category 1 Credit TMorcertificatesdocumentingattendancewillbedistributedtoparticipantsastheydepartthesymposium.ToobtainaCMEcertificate,physiciansmustsubmitacompletedevaluationquestionnaireandaCMEVerificationForm.

Uponrequest,arecordofattendance(certificate)willbeprovidedon-sitetootherhealthcareprofessionalsforrequestingcreditsinaccordancewithstatenursingboards,specialtysocieties,orotherprofessionalassociations.

Christopher G. Wood, MDProgram Co-ChairmanProfessor and Vice ChairmanUrology

Nizar M. Tannir, MDProgram Co-ChairmanAssociate Professor and Vice ChairmanGenitourinary Medical Oncology

Ana Aparicio, MDAssistant ProfessorGenitourinary Medical Oncology

Brian F. Chapin, MDAssistant ProfessorUrology

John W. Davis, MDAssociate ProfessorUrology

Colin P. Dinney, MDProfessor and ChairmanUrology

Jay B. Shah, MDAssistant ProfessorUrology

Arlene Siefker-Radtke, MDAssociate ProfessorGenitourinary Medical Oncology

Gloria CurtisSr. Administrative AssistantGenitourinary Medical Oncology

Carol FourtuniaSr. Administrative AssistantUrology

Constance C. Tierney, CMPManagerCME/Conference Management

Conference Chairmen

Conference Committee

MDAndersonOrganizingCommittee

Friday,November8,20137:00a.m. RegistrationandContinentalBreakfast

7:50 Welcome and Opening Remarks ChristopherG.Wood,MDandNizarM.Tannir,MD

SeSSion i: PeniLe/TeSTiS CAnCeR Moderator: Louis L. Pisters, MD

8:00 Update on Surgical Options for Localized and Locally Advanced Penile Cancer

CurtisA.Pettaway,MD 8:20 Update on Chemotherapy Options for Locally Advanced and Metastatic Penile Cancer LanceC.Pagliaro,MD

8:40 Distinguished Alumnus Presentation Topical Therapy for Non-Muscle Invasive Urothelial Carcinoma:

Past, Present & Future WadeJ.Sexton,MD

9:00 Management of High Risk Stage I Testis Cancer

Case Presentation22yearoldWMpresentswithrighttesticularmass.Metastaticevaluationnegative.AFP90ng/ml,b-HCG<1.0mlU/ml.Undergoesrightradicalorchiectomy.Pathology70%embryonal,25%teratoma,5%seminoma.Invasionintotheretetestis.+LVI.Markersnormalizeappropriatelyaftersurgery.

Observation JoseA.Karam,MD

Chemotherapy JenniferWang,MD

RPLND JohnF.Ward,MD

9:45 Risk Adapted Management of Patients With Advanced Poor-Risk NSGCT LanceC.Pagliaro,MD

ProgramUrologic oncology: Advances in Clinical Practice

10:00 Management of Patients With Platinum Refractory Advanced Germ

Cell Tumors: Role of High-Dose Chemotherapy and Stem Cell Transplantation

YagoNieto,MD 10:15 Questions and Discussion

10:25 Break

10:40 Outcomes and Complications of Post-Chemotherapy RPLND for Metastatic Testis Cancer

LouisL.Pisters,MD 10:55 Management of the Residual Mass in Metastatic Seminoma

s/p Chemotherapy Shi-MingTu,MD

11:10 Case Presentations Moderators: Curtis A. Pettaway, MD and Louis L. Pisters, MD Panelists:JoseA.Karam,MD;YagoNieto,MD;LanceL.Pagliaro,MD;

WadeJ.Sexton,MD;Shi-MingTu,MD;JohnF.Ward,MD

Noon Lunch(Provided)

SeSSion ii: URoTHeLiAL CAnCeR Superficial Bladder CancerModerator: Jay B. Shah, MD

1:00p.m. Novel Approaches to Localized Bladder Cancer ColinP.Dinney,MD

1:10 Controversy: Recurrent T1HG After Induction BCG

Continued Intravesical Therapy is Best ColinP.Dinney,MD

Immediate Cystectomy is Best AshishKamat,MD

Chemoradiation is Best KarenHoffman,MD

Upper Tract DiseaseModerator: Jay B. Shah, MD

1:40 Treatment of Superficial Upper Tract Transitional Cell Carcinoma SurenaF.Matin,MD

1:50 Controversy: HG Tumor of Left Distal Ureter Immediate Distal Ureterectomy is Best NeemaNavai,MD

Neoadjuvant Chemotherapy is Best ArleneSiefker-Radtke,MD

2:00 Questions and Discussion Case Presentations Moderator: Jay B. Shah, MD Panelists:ColinP.Dinney,MD;KarenHoffman,MD;AshishKamat,MD; SurenaF.Matin,MD;NeemaNavai,MD;WadeJ.Sexton,MD; ArleneSiefker-Radtke,MD

2:40 Break

invasive Urothelial CancerModerator: Arlene Siefker-Radtke, MD3:00 Controversy: 63 Year Old Man With T2 Bladder Cancer Open Cystectomy is the Best Option AshishKamat,MD

Robotic Cystectomy is the Best Option JayB.Shah,MD

3:20 Controversy: 63 Year Old Man Undergoing Cystectomy Needs Urinary Diversion Orthotopic Neobladder is Best Choice H.BartonGrossman,MD

Continent Cutaneous Diversion is Best Choice O.LenaineWestney,MD

Ileal Conduit is Best Choice JayB.Shah,MD

3:50 Controversy: 63 Year Old Man With T3 Bladder Cancer Wants Neoadjuvant Chemo MVAC is Best Choice JianjunGao,MD,PhD

Gem/Cis is Best ArleneSiefker-Radtke,MD

4:10 Novel Chemo Situations and Novel Chemo Options ArleneSiefker-Radtke,MD

4:20 Questions and Discussion Case Presentations Moderator: Arlene Siefker-Radtke, MD Panelists:JianjunGao,MD,PhD;H.BartonGrossman,MD;

AshishKamat,MD;JayB.Shah,MD;O.LenaineWestney,MD

5:00 Break

5:15 Andrew C. von Eschenbach Lecture Maximizing Perioperative Management of the IVC for Tumor

Thrombectomy Improves Safety of Radical Nephrectomy MichaelBlute,Sr.,MD

6:00 Reception

Saturday,November9,20137:00a.m. RegistrationandContinentalBreakfast

SeSSion iii: RenAL CAnCeR Moderator: Christopher G. Wood, MD

8:00 Management of Small Renal Mass Debate

Case Presentation70yearoldWMwith3.0cmenhancingrenalmass.PMHsignificantforHtn,CAD,DM

What is the Best Treatment Option? SRM: Active Surveillance SurenaF.Matin,MD

SRM: Intervention JoseA.Karam,MD

8:30 Role of Lymph Node Dissection in Locally Advanced Renal Cell Carcinoma Debate

Case Presentation55yearoldWMwithcT3brightrenaltumor.Noevidenceofmetastaticdisease. Lymph Node Dissection: Pro ChristopherG.Wood,MD

Lymph Node Dissection: Con BrianF.Chapin,MD

9:00 Timing of Cytoreductive Surgery in Metastatic Renal Cell Carcinoma Debate

Case Presentation65yearoldWFpresentswithlocallyadvancedrenalprimarytumorandpulmonarymets.PS1.Nocomorbidconditions. Upfront Cytoreductive Nephrectomy NizarM.Tannir,MD Delayed Cytoreductive Nephrectomy EricJonasch,MD

9:30 What is the Most Appropriate Front Line Therapy for Metastatic Renal Cell Carcinoma Debate

Case Presentation53yearoldWMs/pcytoreductivenephrectomyforaT3aN0M1ccRCC.PS0.LabsWNLexceptHb10.3.Bilateralpulmonarymetastases. First Line Therapy: TKI MarthaP.Mims,MD,PhD First Line therapy: Immunotherapy NizarM.Tannir,MD

10:00 Questions and Discussion

10:10 Break

10:30 Case Presentations Moderator: Christopher G. Wood, MD Panelists:MichaelBlute,Sr.,MD;BrianF.Chapin,MD;EricJonasch,MD;

JoseA.Karam,MD;SurenaF.Matin,MD;MarthaP.Mims,MD,PhD;WadeJ.Sexton,MD;NizarM.Tannir,MD

Noon Lunch(provided)

SeSSion iV: PRoSTATe CAnCeR Radical ProstatectomyModerator: John W. Davis, MD

1:00p.m. How To Improve Urinary and Sexual Function Outcomes SurenaF.Matin,MD

1:15 Discussion/Critique JohnF.Ward,MD;LouisL.Pisters,MD;CurtisA.Pettaway,MD

1:25 How and When to Extend the Pelvic Lymph Node Dissection? BrianF.Chapin,MD

1:40 Discussion/Critique StevenE.Canfield,MD

Health Services Debate: Robot-Assisted Radical Prostatectomy is a Good Investment1:45 Pro JayB.Shah,MD

1:55 Con KarenHoffman,MD

Radiation oncology UpdatesModerator: Deborah A. Kuban, MD

Technique Debate: Best Radiation Therapy for Localized Prostate Cancer2:10 Proton SeungtaekChoi,MD

2:20 IMRT UsamaMahmood,MD

2:30 Brachytherapy StevenJ.Frank,MD

2:40 Discussion/Critique AnaAparicio,MD;WilliamJ.Graber,MD;JohnN.Papadopoulos,MD

3:00 Break

Endocrinology and Systemic Therapy UpdatesModerator: Christopher J. Logothetis, MD

3:15 Testosterone Replacement After Radical Prostatectomy MohitKhera,MD

3:30 Zoledronic Acide vs. Denosumab for Metastatic Prostate Cancer EmilyWang,PharmD

3:45 The Future is Now: Systemic Agents Will Help the Urologist Cure the Uncurrable JohnW.Davis,MD;ChristopherJ.Logothetis,MD

4:00 Discussion/Critique MohitKhera,MD;EmilyWang,PharmD;JohnW.Davis,MD; ChristopherJ.Logothetis,MD

MD Anderson Faculty

Ana Aparicio, MDAssistant ProfessorGenitourinary Medical Oncology

Brian F. Chapin, MDAssistant ProfessorUrology

Seungtaek Choi, MDAssistant ProfessorRadiation Oncology

John W. Davis, MDAssociate ProfessorUrology

Colin P. Dinney, MDChairman & ProfessorUrology

Steven J. Frank, MDAssociate ProfessorRadiation Oncology

Jianjun Gao, MD, PhDAssistant ProfessorGenitourinary Medical Oncology

William J. Graber, MDAssociate ProfessorUrology

H. Barton Grossman, MDClinical ProfessorUrology

Karen Hoffman, MDAssistant ProfessorRadiation Oncology

Eric Jonasch, MDAssociate ProfessorGenitourinary Medical Oncology

Ashish Kamat, MDAssociate ProfessorUrology

Jose A. Karam, MDAssistant ProfessorUrology

Deborah A. Kuban, MDProfessorRadiation Oncology

Christopher J. Logothetis, MDChairman & ProfessorGenitourinary Medical Oncology

Usama Mahmood, MDAssistant ProfessorRadiation Oncology

Case Presentations Moderators: John W. Davis, MD and Ana Aparicio, MDPanelists:BrianF.Chapin,MD;StevenJ.Frank,MD;DeborahA.Kuban,MD;ChristopherJ.Logothetis,MD;JohnF.Ward,MD

4:20 Topics:SequencingandCombiningNovelSystemicAgentsPredictingFailureAfterLocalTherapy.WillNovelRiskClassifiersHelpUs?ImagingChallenges

5:00 Adjourn

Surena F. Matin, MDAssociate ProfessorUrology

Neema Navai, MDAssistant ProfessorUrology

Yago Nieto, MDProfessorStem Cell Transplantation

Lance C. Pagliaro, MDProfessorGenitourinary Medical Oncology

John N. Papadopoulos, MDAssistant ProfessorUrology

Curtis A. Pettaway, MDProfessorUrology

Louis L. Pisters, MDProfessorUrology

Jay B. Shah, MDAssistant ProfessorUrology

Andrew C. von Eschenbach LectureMichael Blute, Sr., MDChief of Urology, Massachusetts General HospitalProfessor of Urology, Harvard Medical SchoolBoston, Massachusetts

Distinguished AlumniWade J. Sexton, MDAssociate Professor University of South FloridaDepartment of Genitourinary OncologyDirector, Urologic Oncology Fellowship ProgramMoffitt Cancer CenterTampa, Florida

Guest FacultySteven E. Canfield, MDAssociate ProfessorDivision of Urology/Department of SurgeryUT Health Science CenterHouston, Texas

Mohit Khera, MDAssistant ProfessorScott Department of Urology/Baylor ClinicBaylor College of MedicineHouston, Texas

Martha P. Mims, MD, PhDAssociate ProfessorDepartment of Hematology & OncologyBaylor College of MedicineHouston, Texas

Arlene Siefker-Radtke, MDAssociate ProfessorGenitourinary Medical Oncology

Nizar M. Tannir, MD Associate Professor & Vice ChairmanGenitourinary Medical Oncology

Shi-Ming Tu, MDProfessorGenitourinary Medical Oncology

Emily Wang, PharmDClinical Pharmacy SpecialistPharmacy

Jennifer Wang, MDAssistant ProfessorGenitourinary Medical Oncology

John F. Ward, MDAssociate ProfessorUrology

O. Lenaine Westney, MDAssociate ProfessorUrology

Christopher G. Wood, MDProfessor & Vice ChairmanUrology

Urologic oncology: Advances in Clinical PracticeOn-siteregistrationopensat7:00a.m.onFriday, November 8, 2013.Theconferencewillbeginat7:50amonFriday, November 8, 2013 andadjournonSaturday,November9,2013at5:00p.m.Advanceregistrationisencouragedasspaceandmaterialsarelimited.Pleaseseetheregistrationformforapplicablefees.

Thefullconferenceregistrationfeeincludesthetuition,syllabus,breakfasts,breaks,lunches,andreception.

The deadline for advance registration is Friday, October 18, 2013.

There are three ways to register:•Mailto:CME/ConferenceManagement–Unit1381,TheUniversityofTexas

MDAndersonCancerCenter,P.O.Box301439,Houston,TX77230-1439•Faxto:713-794-1724•On-lineatwww.mdanderson.org/conferences

We accept the following forms of payment:•Check(payablethroughU.S.banksonly)•MoneyOrder•CreditCards(MasterCard,VISA,andAmericanExpress)•Cash(on-siteregistrationonly)

Whenregisteringonlineareceipt/confirmationletterwillbeautomaticallye-mailedtothee-mailaddressyoulistontheregistrationform.Ifyouregisterbyfaxormail,areceipt/confirmationletterwillbesenttoyouwithintenworkingdaysofreceiptofyourfee.

Registration Information

Refund/CancellationPolicy Theregistrationfee,minusa$50administrativehandlingfee,isrefundableifawrittenrequestisreceivedonorbeforeOctober18,2013.Norefundswillbegrantedafterthatdate.Therequestforaregistrationrefundmustincludethetaxidentificationnumberofthecompanyorinstitutionifregistrationwaspaidbyacompanyorinstitutioncheck.

TheDepartmentofCME/ConferenceManagementreservestherighttocancelactivitiespriortothescheduleddate,iflowenrollmentorothercircumstancesmakeitnecessary.Eachregistrantwillbenotifiedbymail,e-mail,oratthephoneorfaxnumbersgivenontheregistrationform.Incaseofactivitycancellation,theliabilityoftheDepartmentofCME/ConferenceManagementislimitedtotheregistrationfee.CME/ConferenceManagementwillrefundthefullregistrationfee.

TheDepartmentofCME/ConferenceManagementreservestherighttolimitthenumberofparticipantsinaprogramandisnotresponsibleforanyexpensesincurredbyanindividualwhoseregistrationisnotconfirmedandforwhomspaceisnotavailable.

SpecialAssistanceContacttheDepartmentofCME/ConferenceManagementat713-792-2223ortollfreeat866-849-5866ifyouhaveanyspecialdietaryorADAaccommodationneeds.

Accommodations• Ablockofroomshasbeenreservedforconferenceattendeesatthe Houston Marriott at the Texas Medical Center,6580FanninStreet,Houston,Texas.• Earlyhotelreservationissuggested.Tomakereservations,pleasecallMarriott

Reservationsat800-228-9290andidentifyyourselfaspartoftheMDAndersonUrologicOncologyConference

• Thespecialmeetingrateis$114.00singleordoubleoccupancy.Pleaseadd17% TexasStateandlocaltaxes.ReservationsanddepositsreceivedafterOctober17, 2013willbeconfirmedifspaceisavailableandatcurrenthotelpublishedguest

roomrates.

Please let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity. Fax or e-mail CME/Conference Management. All responses will be forwarded to the Program Chairs for consideration.

GroundTransportation (prices are subject to change and variable depending on location of conference)• Houstonisservedbytwoairports,GeorgeBushIntercontinental(IAH)and

WilliamP.Hobby(HOU).

• Taxicabsareavailableatanestimatedcostfor$50-60,toorfromWilliamP.HobbyAirportorGeorgeBushIntercontinentalAirport.

• SuperShuttleoperatesashuttlebusbetweenGeorgeBushIntercontinentalAirportandtheHoustonMarriottattheTexasMedicalCenterfor$27one-wayand$54round-trip.Formoreinformation,call713-523-8888ortoll-freeat800-258-3826oron-lineatwww.supershuttle.com.

• SuperShuttleoperatesashuttlebusbetweenWilliamP.HobbyAirportandtheHoustonMarriottattheTexasMedicalCenterfor$24one-wayand$48round-trip.Formoreinformation,call713-523-8888ortoll-freeat800-258-3826oron-lineatwww.supershuttle.com.

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable exper-tise on rare occasions necessitated by illness, schedule conflicts, and so forth.

Photographing, audio taping and videotaping are prohibited.

CON

FERE

NCE

REG

ISTR

ATIO

N -

PS10

0595

/111

409

8th

Urol

ogic

Onco

logy

: Ad

vanc

es in

Clin

ical P

ract

ice —

Nov

embe

r 8-9

, 201

3

THIS

IS N

OT A

SEL

F-M

AILE

R - A

ddre

ss to

: 8t

h Ur

olog

ic O

ncol

ogy:

Adv

ance

s in

Clin

ical

Pra

ctic

eN

ovem

ber 8

-9, 2

013

Depa

rtmen

t of C

ME/

Conf

eren

ce M

anag

emen

t Un

it 13

81Th

e Un

iver

sity

of T

exas

MD

Ande

rson

Can

cer C

ente

r PO

Box

301

439,

Hou

ston

, TX

7723

0-14

39or

fax

to 7

13-7

94-1

724

Mak

e ch

eck

or m

oney

ord

er p

ayab

le to

: Th

e Un

iver

sity

of T

exas

MD

Ande

rson

Can

cer C

ente

r

GENE

RAL C

ONFE

RENC

E RE

GIST

RATI

ON FE

ESPh

ysic

ians

1 P

ostm

arke

d on

or b

efor

e Oc

t. 18

, 201

3 .....

.$25

0.00

1 P

ostm

arke

d af

ter O

ct. 1

8, 20

13 ...

........

........

$300

.00

Stud

ents

/ Tr

aine

es /

PAs /

Ad

vanc

ed N

urse

Pra

ctiti

oner

s1 P

ostm

arke

d on

or b

efor

e Oc

t. 18

, 201

3 .....

.$55

.00

1 P

ostm

arke

d af

ter O

ct. 1

8, 20

13 ...

........

........

$80.0

0

Last

Nam

e

Fi

rst

M

I

H

ighe

st D

egre

e

Depa

rtmen

t (in

clud

e bo

x no

.)

Sp

ecia

lty

Inst

itutio

n

Ph

ysic

ian

Stre

et

City

S

tate

/For

eign

Cou

ntry

/Zip

or M

ail C

ode

Dayt

ime

Phon

e (w

ith a

rea

code

)

Cel

l Pho

ne (w

ith a

rea

code

)

F

ax (w

ith a

rea

code

)

E-m

ail A

ddre

ss

Emer

genc

y Co

ntac

t

Pho

ne (w

ith a

rea

code

)

Char

ge th

e fo

llow

ing:

o

VISA

oM

aste

rCar

d

o

Amer

ican

Exp

ress

Cred

it Ca

rd N

umbe

r

Exp

iratio

n Da

te

Busi

ness

Uni

t D

epar

tmen

t

Fun

d Gr

oup

F

und

F

und

Type

PC

By

Pr

ojec

t

Ac

tivity

Cred

it Ca

rd H

olde

r Nam

e (F

irst/

Last

)

Cre

dit C

ard

Hold

er B

illin

g Ad

dres

s &

ZIP

Cod

e

Auth

orize

d Si

gnat

ure

REQU

IRED

for c

redi

t car

d or

IDT

MD

Ande

rson

Em

ploy

ee ID

No.

(REQ

UIRE

D)

IDT

Appr

over

Nam

e (F

irst/

Last

) ple

ase

prin

t

I

DT A

ppro

ver E

-mai

l

oYe

s

o

No

MD

And

erso

n In

terd

epar

tmen

tal T

rans

fer (

IDT)

No.

:

Depa

rtmen

t of C

ME/

Conf

eren

ce M

anag

emen

t - U

nit 1

381

The

Univ

ersi

ty o

f Tex

as M

D An

ders

on C

ance

r Cen

ter

#176

700/

1114

09/ P

S100

595

PO B

ox 3

0143

9Ho

usto

n, T

X 77

230-

1439

Non

-Pro

fit O

rg.

U.S.

Pos

tage

PAID

Perm

it N

o. 7

052

Hous

ton,

TX